FLXN Flexion Therapeutics Inc.

17.51
-0.32  -2%
Previous Close 17.83
Open 18.01
Price To Book 92.16
Market Cap 668,440,048
Shares 38,174,760
Volume 1,035,534
Short Ratio
Av. Daily Volume 956,772
Stock charts supplied by TradingView

NewsSee all news

  1. Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

    Xenon's Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered

  2. Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020

    Fourth-quarter 2019 revenue estimated to be approximately $23.7 millionFull-year 2019 revenue estimated to be approximately $73 million, representing year-over-year growth of more than 220%Flexion provides 2020 product

  3. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800

  4. Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label

    Conference call scheduled for Friday, December 27, 2019 at 8:00 a.m. ET BURLINGTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the U.S. Food and Drug

  5. Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis

    BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial discontinued - noted November 7, 2019.
Zilretta
Osteoarthritis of the hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
FDA Approval announced December 26, 2019. New label notes that efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Zilretta - FX006 label update
Osteoarthritis of the knee
Phase 2 trial to be completed 1H 2021.
Zilretta - FX006
Shoulder osteoarthritis (OA) and frozen shoulder
Phase 1 trial to commence 4Q 2019 with initial data due in 2021.
FX201
Osteoarthritis (OA)
Phase 2 commencement of enrolment announced December 17, 2019. Trial to be completed 1H 2021.
Zilretta
Osteoarthritis of the Shoulder and Adhesive Capsulitis

Latest News

  1. Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

    Xenon's Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered

  2. Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020

    Fourth-quarter 2019 revenue estimated to be approximately $23.7 millionFull-year 2019 revenue estimated to be approximately $73 million, representing year-over-year growth of more than 220%Flexion provides 2020 product

  3. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800

  4. Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label

    Conference call scheduled for Friday, December 27, 2019 at 8:00 a.m. ET BURLINGTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the U.S. Food and Drug

  5. Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis

    BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA

  6. Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder

    BURLINGTON, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020. Dr. Bodick

  7. Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain

    NFL broadcaster Solomon Wilcots to go "Knee to Knee" as moderator of discussion with 1980 USA hockey team captain Mike Eruzione, NFL Hall of Fame member Rod Woodson and retired MLB player Chris DickersonOrthopaedic

  8. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150

  9. Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings

    Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scalesIn this analysis of concordant pain reporters,

  10. Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights

    Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2Full-year 2019 ZILRETTA net sales guidance range tightened to

  11. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500

  12. Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019

    BURLINGTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets

  13. Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis

    In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy  A single intra-articular injection of FX201 has the potential to both

  14. Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

    BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to

  15. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425

  16. Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)

    BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics (NASDAQ:FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012 playoff teams, to raise

  17. Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BURLINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual Cell

  18. Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.

    Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemicExhibit will be on display Sept. 23-28 at the

  19. Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

    Flexion's new locally delivered product candidate, FX301, will combine Xenon's NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogelFX301 is a potential first-in-class therapy with the aim of providing pain

  20. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to nine new employees consisting of an aggregate of 25,900 stock options and 4,350

  21. Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference

    BURLINGTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led